


HR

FOR OUTSIDE THE US AND CANADA ONLY

# LIAISON<sup>®</sup> MUREX Anti-HEV DIAGNOSTIC SOLUTION

The combined testing solution  
for the detection of antibodies  
to Hepatitis E virus

HEPATITIS AND RETROVIRUSES



DiaSorin

The Diagnostic Specialist

# LIAISON® MUREX Anti-HEV IgG & IgM

The first fully automated chemiluminescence immunoassays for the diagnosis of HEV infection and the selection of organ, tissue and cells post-mortem donors.

## Clinical overview

- Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide<sup>1</sup>
- HEV infection is mostly asymptomatic and self-limiting but it can lead to fulminant hepatitis in pregnant women and patients with pre-existing liver disease
- The concentration of anti-HEV IgG antibodies could be useful in determining which level of IgG would be protective after natural infection or vaccine administration<sup>2</sup>
- According to EASL guidelines, all patients with hepatitis should be tested for HEV, as part of the first-line virological investigation<sup>3</sup>
- Most recent evidence on HEV transmission after transplantation suggests the need for a systematic screening of donors, particularly in endemic regions<sup>4</sup>

## The value of the DiaSorin solution

Boost the global response to HEV with DiaSorin solution.

- Provide reliable results choosing the good performances of the LIAISON® MUREX HEV assays
- Enhance the diagnostic value of your results providing the quantification of IgG anti-HEV antibodies
- Be recognized as a reference Center for the organ donors selection by using the widest fully automated, chemiluminescent panel validated for the use on samples collected from dead donors
- Improve your capability to support the clinical patients management thank to the differentiation of five different viral hepatitis infections
- Improving the efficiency and the workflow of your laboratory through the consolidation on the LIAISON® XL platform of the widest automated menu for the diagnosis of Infectious Diseases and Viral Hepatitis

## The assays features

### Clinical Performances:

Anti-HEV IgM: 97.93% Specificity; 98.44% (PCR positive) Sensitivity  
Anti-HEV IgG: 99.22% Specificity; 97.92% Sensitivity

### Expression of results:

Anti-HEV IgG: quantitative (IU/mL)  
Anti-HEV IgM: qualitative (index)

### Throughput:

LIAISON® XL: 171 test/h  
LIAISON®, LIAISON® XS: 86 test/h

### Time to first result:

35 minutes

### Sample Type:

Human Serum  
Human Plasma (Li-heparin, Na-heparin, K2-EDTA, K-oxalate, ACD, CPDA)

### Reagent, Controls and Calibrators:

Ready to use

## Ordering Information

Description	Kit configuration	Part number
LIAISON® Murex Anti-HEV IgG	100 tests	311270
LIAISON® Murex Control Anti-HEV IgG	2 levels/2 vial each	311271
LIAISON® Murex Anti-HEV IgM	100 tests	311280
LIAISON® Murex Control Anti-HEV IgM	2 levels/2 vial each	311281

### References

1. Mehnaaz S Khuroo et al., J Viral Hepat. 2016 Feb;23(2):68-79
2. Kamar N. et al., Clin Microbiol Rev 2014;27:116-138
3. EASL Clinical Practice Guidelines on hepatitis E virus infection. 2018
4. Pourbaix A. et al., Transpl Infect Dis. 2017 Feb;19(1)

### Available on LIAISON® systems

Product availability subject to required regulatory approval

### Diasorin S.p.A

Via Crescentino SNC, 13040 Saluggia (VC) - Italy  
www.diasorin.com